Bile Acid Malabsorption in Patients with Neuroendocrine Tumors.

Abstract

Chronic diarrhea in patients with neuroendocrine tumors (NET) may be caused by bioactive products of NET, bile acid malabsorption (BAM), ileal resection (IR) or steatorrhea. To quantitate BA and fat malabsorption in NET with diarrhea. Part of evaluation in medical oncology clinical practice, 67 patients [42F, 25M; median age 64.0 y (17.0 IQR)] with well-differentiated NET and diarrhea underwent clinically indicated measurements of 48-h fecal BA [(FBA), fecal weight (normal < 400g/48h), fecal fat (normal < 7g/day) in n = 52] and fasting serum 7αC4 (marker of hepatic BA synthesis, n = 30) between 01/2018 and 11/2020. IR had been performed in 45 patients. BAM diagnosis was based on FBA criteria: elevated total FBA (> 2337µmol/48h) or > 10% primary FBA or combination > 4% primary FBA plus > 1000µmol total FBA/48h. We also measured fecal elastase (for pancreatic insufficiency) in 13 patients. BAM was present in 48/52 (92%) patients with NET. There were significant correlations between total FBA and 48-h fecal weight (Rs = 0.645, P < 0.001). Mean length of IR was 47cm; in patients with IR < 25cm, total FBA was elevated in 85% and primary FBA > 10% in 69%. In 22 patients with no IR, 13/15 tested (87%) had BAM. Among 6 patients with pancreatic NET and no IR, 80% had BAM. Fecal fat was ≥ 15g/day in 18/42 (43%). In 4/17 (24%) with IR < 25cm and 8/19 (42%) patients with IR > 25cm fecal fat was 44.0 (40.5) and 38.0 (38.0)g/day, respectively. A majority of patients with NET and diarrhea had BAM, even with < 25cm or no IR.